1.3 Early detection
In patients with pre-existing pre-leukaemic disorders (e.g. myelodysplasia, other myeloid neoplasms) and pre-disposing genetic disorders, routine care of these should include full blood counts and bone marrow biopsies at appropriate clinical intervals. This enables early detection in many circumstances. The frequency of blood tests and any bone marrow biopsies should be determined by standard frequency appropriate to the pre-existing or pre-disposing condition. For some conditions, such as myelodysplasia, validated risk assessment tools are available to guide practice in this regard.
There are no screening programs for AML.